Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis.
about
The endocannabinoid system as an emerging target of pharmacotherapyNeural Plasticity in Multiple Sclerosis: The Functional and Molecular BackgroundBrain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid systemInteraction between Cannabinoid System and Toll-Like Receptors Controls InflammationCannabinoids as novel anti-inflammatory drugs.Cannabinoids and Viral Infections.A synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in ratsRegulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites.Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotectionEndocannabinoids and immune regulation.Regulation of neurite outgrowth by G(i/o) signaling pathways.New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosisAnandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB(1) receptorsThe therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptorCannabinoid CB2 receptors in human brain inflammation.Targeting the endocannabinoid system in treating brain disorders.Anandamide: an update.Protective Action of Anandamide and Its COX-2 Metabolite against l-Homocysteine-Induced NLRP3 Inflammasome Activation and Injury in Podocytes.Targeting the endocannabinoid system: to enhance or reduce?Endocannabinoids: A Promising Impact for Traumatic Brain Injury.Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction.Cannabinoids, multiple sclerosis and neuroprotection.Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier.Neuroinflammation as a possible link between cannabinoids and addiction.Nicotinic acid-mediated activation of both membrane and nuclear receptors towards therapeutic glucocorticoid mimetics for treating multiple sclerosis.Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB.Disruption of IFN-gamma- mediated antiviral activity in neurons: the role of cannabinoidsModulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli.Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats.The endocannabinoid system in canine Steroid-Responsive Meningitis-Arteritis and Intraspinal Spirocercosis.CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation.Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis
P2860
Q24648473-8CEBFF71-ADE2-476B-811A-55FF78393DD0Q26801046-4279640E-A4CE-4105-BAB4-B798663CF807Q26865295-1972A080-42C8-4A65-9337-2BBA8F1C6DC6Q28066215-61B11747-4A9B-428D-8F62-7F4CA4203565Q33688381-5220904E-AACF-4AEB-B131-F6A58859C171Q33992923-2CCE287B-887B-4A52-AB25-1E224DA901B3Q34308648-B3AAC482-5D95-4B2A-852A-7481C87A2B9BQ34471868-DC777B61-F009-473E-B902-8826BBB2EA2FQ34597537-723EFB36-AEBB-433D-B0F7-7C536A93D1ACQ34607419-A1DB8D60-93CC-4C25-BD22-B8FAC32A69B1Q34746354-0D503864-82BF-4193-9C37-E696AF908AB9Q35098586-B383C6F8-ABC1-45B0-8069-E5AC8A7BFA7CQ35213727-9F336FEC-65B5-49D6-88B6-CDD1DC298B81Q36341688-C5254737-AC22-4E54-9BCB-B25396212480Q36416340-C28A822A-8B60-4395-8ADF-EE33CD1C7BD9Q36416377-0B503B21-29F2-44DF-9B5A-AB94D3865A9DQ36425999-840E064B-D88B-4272-BEB3-7C25A228C845Q36709628-471CE42F-D72A-4498-94B4-B54F24579491Q37062591-193D3832-0CC4-40BF-B5F7-F4C7E01AC5E1Q37150745-2540D186-9984-4CCB-BCD4-34A52CDA7880Q37648343-237DBE00-3E77-4978-80FC-291744D2156AQ37859402-C05ACD2F-BCBD-4830-9A16-15B0DC912DFCQ37960199-028E1EAC-5992-456B-8967-FCF9129B57B3Q38220272-F829456B-86F9-48BF-8B2A-67A72EB9B668Q38278954-974E4CCF-4C24-405E-8225-2D053A0C0076Q39303280-08F45609-6866-45D8-9F67-DCC86B4E01CEQ39831195-38DEFD4C-D901-4B0B-B285-98C1127F9192Q39969705-1C170F3C-9792-4924-BE4F-31830D99E0CFQ46639969-4E02EB80-5771-4961-8C33-60DF63D836B6Q46660450-6F30DD92-98FD-4923-932C-24B2614D315CQ48097673-049C8241-F8B5-466D-B2C3-1B244EC55A03Q48486771-57FDC5B4-A4D5-4516-AB36-E23F1F73AC57Q58775742-47BF72C1-BE17-4BE8-89B0-FF18D0A8767B
P2860
Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Pharmacological modulation of ...... l model of multiple sclerosis.
@en
type
label
Pharmacological modulation of ...... l model of multiple sclerosis.
@en
prefLabel
Pharmacological modulation of ...... l model of multiple sclerosis.
@en
P2093
P2860
P50
P1476
Pharmacological modulation of ...... al model of multiple sclerosis
@en
P2093
Carmen Guaza
Fernando Correa
Giorgio Ortar
Marta Valenti
P2860
P304
P356
10.1111/J.1471-4159.2004.02979.X
P407
P577
2005-03-01T00:00:00Z